Fernando Rivera
Impact in
- Otorhinolaryngology top 0.1%
- Head and Neck Cancer Studies
- Oncology top 0.1%
- Colorectal Cancer Treatments and Studies
- Cancer Treatment and Pharmacology
- Cancer Immunotherapy and Biomarkers
Papers in
- Oncology 129
- Colorectal Cancer Treatments and Studies 102
- Cancer Treatment and Pharmacology 34
- Pancreatic and Hepatic Oncology Research 22
- Cancer Immunotherapy and Biomarkers 9
-
- Gastric Cancer Management and Outcomes 30
- Lung Cancer Treatments and Mutations 11
- Co-authors
- Eduardo Díaz‐Rubio (26 shared papers)Arié Figer (7 shared papers)Stephen Clarke (6 shared papers)Leonard B. Saltz (4 shared papers)Mikhail Lichinitser (3 shared papers)Tsai‐Shen Yang (3 shared papers)Florin Sirzén (3 shared papers)Sheryl Koski (4 shared papers)
- Journals
- Journal of Clinical Oncology (46 papers)Annals of Oncology (28 papers)Clinical & Translational Oncology (14 papers)European Journal of Cancer (8 papers)The Oncologist (5 papers)
- Partner nations
- SpainUnited StatesFrance
In The Last Decade
Fernando Rivera
165 papers receiving 13.1k citations
Fernando Rivera's Hit Papers
Peers
Comparison fields: 5 of 121
- Otorhinolaryngology 1.5k
- Oncology 8.5k
- Hepatology 1.7k
- Pulmonary and Respiratory Medicine 2.9k
- Cancer Research 1.3k
Countries citing papers authored by Fernando Rivera
This map shows the geographic impact of Fernando Rivera's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Fernando Rivera with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Fernando Rivera more than expected).
Fields of papers citing papers by Fernando Rivera
This network shows the impact of papers produced by Fernando Rivera. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Fernando Rivera. The network helps show where Fernando Rivera may publish in the future.
Co-authors
The 25 scholars most cited alongside Fernando Rivera, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 169 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Platinum-Based Chemotherapy plus Cetuximab in Head and Neck Cancer Hit paper breakdown → | 2008 | 2734 |
| 2 | Bevacizumab in Combination With Oxaliplatin-Based Chemotherapy As First-Line Therapy in Metastatic Colorectal Cancer: A Randomized Phase III Study Hit paper breakdown → | 2008 | 2339 |
| 3 | Randomized, Phase III Trial of Panitumumab With Infusional Fluorouracil, Leucovorin, and Oxaliplatin (FOLFOX4) Versus FOLFOX4 Alone As First-Line Treatment in Patients With Previously Untreated Metastatic Colorectal Cancer: The PRIME Study Hit paper breakdown → | 2010 | 1393 |
| 4 | Randomized Phase III Study of Capecitabine Plus Oxaliplatin Compared With Fluorouracil/Folinic Acid Plus Oxaliplatin As First-Line Therapy for Metastatic Colorectal Cancer Hit paper breakdown → | 2008 | 670 |
| 5 | OPTIMOX1: A Randomized Study of FOLFOX4 or FOLFOX7 With Oxaliplatin in a Stop-and-Go Fashion in Advanced Colorectal Cancer—A GERCOR Study Hit paper breakdown → | 2006 | 607 |
| 6 | Pembrolizumab versus chemotherapy for microsatellite instability-high or mismatch repair-deficient metastatic colorectal cancer (KEYNOTE-177): final analysis of a randomised, open-label, phase 3 study Hit paper breakdown → | 2022 | 533 |
| 7 | PEAK: A Randomized, Multicenter Phase II Study of Panitumumab Plus Modified Fluorouracil, Leucovorin, and Oxaliplatin (mFOLFOX6) or Bevacizumab Plus mFOLFOX6 in Patients With Previously Untreated, Unresectable, Wild-Type KRAS Exon 2 Metastatic Colorectal Cancer Hit paper breakdown → | 2014 | 489 |
| 8 | 2009 | 435 | |
| 9 | 2012 | 369 | |
| 10 | 2007 | 209 | |
| 11 | 2009 | 201 | |
| 12 | 2020 | 145 | |
| 13 | 2006 | 138 | |
| 14 | 2007 | 105 | |
| 15 | 2009 | 100 | |
| 16 | 2014 | 94 | |
| 17 | 2009 | 83 | |
| 18 | 2010 | 81 | |
| 19 | 2012 | 79 | |
| 20 | 2017 | 79 |
About Fernando Rivera
Fernando Rivera is a scholar working on Oncology, Pulmonary and Respiratory Medicine, Cancer Research, Pathology and Forensic Medicine and Surgery, having authored 169 papers that have together received 13.4k indexed citations. Recurring topics across this work include Colorectal Cancer Treatments and Studies (102 papers), Cancer Treatment and Pharmacology (34 papers), Gastric Cancer Management and Outcomes (30 papers), Cancer Genomics and Diagnostics (25 papers), Pancreatic and Hepatic Oncology Research (22 papers), Genetic factors in colorectal cancer (20 papers), Lung Cancer Treatments and Mutations (11 papers) and Cancer Immunotherapy and Biomarkers (9 papers). The work is most often cited by research in Otorhinolaryngology (1.5k citations), Oncology (8.5k citations), Hepatology (1.7k citations), Pulmonary and Respiratory Medicine (2.9k citations) and Cancer Research (1.3k citations). Fernando Rivera has collaborated with scholars based in Spain, United States and France. Frequent co-authors include Eduardo Díaz‐Rubio, Arié Figer, Stephen Clarke, Leonard B. Saltz, Mikhail Lichinitser, Tsai‐Shen Yang, Florin Sirzén, Sheryl Koski, Félix Couture and Jim Cassidy. Their work appears in journals such as Journal of Clinical Oncology, Annals of Oncology, Clinical & Translational Oncology, European Journal of Cancer and The Oncologist.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.